Inflammation and Benign Prostatic Hyperplasia – A Histopathological Correlation

Received: 20-Jul-2024, Manuscript No. ijmrhs-24-142654; Accepted Date: Aug 16, 2024 ; Editor assigned: 25-Jul-2024, Pre QC No. ijmrhs-24-142654(PQ); Reviewed: 02-Aug-2024, QC No. ijmrhs-24-142654(Q); Revised: 10-Aug-2024, Manuscript No. ijmrhs-24-142654(R); Published: 20-Aug-2024

Introduction

The correlation between inflammation and Benign Prostatic Hyperplasia (BPH) has been an area of growing interest in urological research. Studies suggest that chronic inflammation may play a significant role in the development and progression of BPH [1-3].

Inflammation is thought to contribute to prostatic enlargement and symptoms of BPH in several ways. Firstly, inflammatory cells release cytokines and growth factors that can stimulate prostatic tissue growth. Secondly, this inflammatory process can lead to fibrosis and reduced tissue elasticity, exacerbating lower urinary tract symptoms [4-6].

Interestingly, histological examinations of BPH tissues often reveal the presence of inflammatory cells, supporting the theory of an inflammatory component in BPH pathogenesis [4]. The severity of inflammation has also been correlated with the dgree of urinary symptoms, suggesting a direct link between inflammation and symptomatology [5].

Moreover, emerging evidence indicates that metabolic syndrome, which is associated with systemic inflammation, may be a risk factor for BPH. This further underscores the potential role of inflammation in BPH [7, 8].

While the exact mechanisms are still being elucidated, substantial evidence suggests a significant correlation between inflammation and benign prostatic hyperplasia. This understanding could lead to new therapeutic strategies targeting the inflammatory pathways in BPH management [9, 10].

Several trials have investigated the relationship between CP and BPH, focusing on the efficacy of anti-inflammatory agents in the treatment of BPH symptoms. For example, the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and inhibitors of Cyclooxygenase-2 (COX-2) has been explored, with some studies reporting improvements in symptoms and urinary flow rates in patients with BPH. These findings support the hypothesis that inflammation plays a role in BPH pathogenesis and symptomatology [11].

Moreover, research into molecular markers of inflammation and proliferation within prostatic tissue aims to elucidate the specific pathways through which CP may influence the development of BPH. Identifying these markers could lead to targeted therapies that address the underlying inflammatory processes in patients with coexisting CP and BPH [12, 13].

The presence of inflammation of the prostate is dependent on many factors including geographical location, socio-economic status, diet, and hygiene of the patients. There is a dearth of literature correlating the levels of inflammation in patients requiring surgery for BPE in India.

The pathophysiology linking CP and BPH involves several key mechanisms [9, 10].

• Inflammatory mediators: Chronic inflammation can lead to the secretion of cytokines and growth factors, which may stimulate prostatic stromal and epithelial cell proliferation, contributing to the development of BPH.

• Hormonal influence: The role of androgens, particularly Di- Hydro Testosterone (DHT), in the development of BPH is well-documented. Inflammation may further modulate the hormonal milieu, enhancing the sensitivity of prostatic tissue to androgens.

• Immune response: The immune response triggered by CP may exacerbate tissue damage and fibrosis, creating a microenvironment conducive to the development of BPH.

This study was based on an ambispective analysis of slides of patients having been operated on with Transurethral Resection of Prostate (TURP) for Benign Prostatic Enlargement (BPE).

Methods

This was an ambispective study undertaken between May 2004 to July 2011 and involved an analysis of prostatic specimens received after TURP and open prostatectomy done on patients with indications for surgery for Benign Prostatic Enlargement.

All the prostatic specimens fixed in 10% formalin were received. They were weighed and subjected to a careful detailed gross examination, then fixed in 10% buffered formalin for 24 hours. After fixation, the bits were given and processed routinely. The TURP chips were weighed, and the entire specimen was embedded. Sections were prepared after routine processing and then stained with Hematoxylin and Eosin. Standard statistical methods were used.

Results

During the course of the study, a total of 391 samples from patients having undergone TURP for Benign Prostatic Enlargement were received of these, 39 harbored prostatic malignancies (39/391, 10%). The remaining 369 patients had a pathological diagnosis of Benign Prostatic Hyperplasia (BPH) on their HPE. Most of these patients with BPH were in the sixth and seventh decade of life (264/369, 71%) of the patients with BPH, 310 (84%) had Adenomatous Hyperplasia, 59 (16%) had Stromal Hyperplasia and 46 (12.5%) had a Basal Cell Hyperplasia pattern on their HPE. There were various associated findings with BPH, of which chronic prostatitis was most common, seen in 186 patients (50.4%) (Figure 1). The various other findings are detailed in (Table 1).

Figure 1. Slide showing features of chronic prostatitis (High Power)

Chronic prostatitis was observed in the maximum number of BPH cases (50.4%). 7 cases (1.9%) had evidence of Acute Prostatitis and micro-abscesses were seen in 8 cases (2.2%). Granulomatous prostatitis was seen in 2 cases (0.5%) (Figure 2).

Figure 2. Slide showing features of granulomatous prostatitis (High power)

The various histopathological findings that were observed in the cases with chronic prostatitis were:

• Inflammatory cell infiltration: There was the presence of inflammatory cells within the prostate gland. This included lymphocytes, macrophages, and occasionally neutrophils. The distribution of these cells was focal and diffuse, and they were often found in the stroma and around the glandular epithelium.

• Glandular changes: In response to inflammation, there was evidence of glandular disruption and atrophy. The epithelial cells exhibited reactive changes such as nuclear enlargement and increased cytoplasmic volume. In some cases, the glandular architecture was distorted due to the inflammatory process.

• Stromal changes: The stroma showed fibrosis and increased density of the connective tissue as a response to chronic inflammation.

Discussion

Chronic Prostatitis (CP) and Benign Prostatic Hyperplasia (BPH) are two prevalent conditions affecting the prostate gland, yet their association, pathophysiology, and histopathological correlations present a complex interplay that has been the subject of various clinical and research trials. While CP is characterized by inflammation of the prostate, BPH is primarily a condition marked by the noncancerous enlargement of the prostate gland. Despite these distinct definitions, emerging evidence suggests a potential overlap in their pathophysiological mechanisms and patient symptomatology.

The association between CP and BPH is multifaceted, involving inflammatory, hormonal, and growth factor-mediated pathways. Several studies have proposed that chronic inflammation, as seen in CP, may contribute to the development and progression of BPH.

This is supported by histopathological analyses showing inflammatory infiltrates in prostate tissue samples from patients with BPH, suggesting a possible role of inflammation in prostatic tissue proliferation and hyperplasia.

Histopathologically, both CP and BPH exhibit distinct yet potentially overlapping features. Prostate tissue from patients with CP often shows inflammatory cell infiltrates, fibrosis, and occasionally granulomatous reactions. In contrast, BPH tissue is characterized by an increase in epithelial and stromal cell components, leading to nodular hyperplasia. However, the presence of inflammatory cells within BPH nodules suggests an interplay between inflammation and hyperplasia.

Conclusion

The association between CP and BPH underscores the importance of understanding the complex interplay of inflammatory, hormonal, and growth factor-mediated pathways in these conditions. While distinct in their primary manifestations, the overlap in pathophysiology and histopathological features suggests that inflammation may serve as a common denominator driving the progression of both these conditions. Continued research and clinical trials focusing on this interconnection are essential for developing more effective diagnostic and therapeutic strategies for patients suffering from CP, BPH, or both.

References

1. Moore, Robert A. "Inflammation of the prostate gland." The Journal of Urology. Vol. 38, No. 2, 1937, pp. 173-82. Google Scholar          Crossref
2. MM, COLLINS. "How common is prostatitis? A national survey of physician visits." The Journal of Urology. Vol. 159, 1998, pp. 1224-28. Google Scholar          Crossref        
3. Sauver, Jennifer L. St, et al. "Longitudinal association between prostatitis and development of benign prostatic hyperplasia." The Journal of Urology. Vol. 71, No. 3, 2008, pp. 475-79. Google Scholar          Crossref
4. Robert, Grégoire, et al. "Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemically analysis." The Prostate. Vol. 69, No. 16, 2009, pp. 1774-80. Google Scholar          Crossref
5. Nickel, J. Curtis, et al. "The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial." European Urology. Vol. 54, No. 6, 2008, pp. 1379-84. Google Scholar          Crossref  
6. Roehrborn, C. G. K. S. "10 The impact of acute or chronic inflammation in baseline biopsy on the risk of progression in the MTOPS study." European Urology Supplements. Vol. 3, No. 4, 2005. Google Scholar          Crossref
7. Lv, Kaikai, et al. "The causal effect of metabolic syndrome and its components on benign prostatic hyperplasia: A univariable and multivariable Mendelian randomization study." The Prostate. Vol. 83, No. 14, 2023, pp. 1358-64. Google Scholar          Crossref
8. Lee, Jooho, et al. "Lowering the percent body fat in the obese population might reduce male lower urinary tract symptoms." World Journal of Urology. Vol. 41, No. 6, 2023, pp. 1621-27. Google Scholar          Crossref
9. Horsanali, Mustafa O., et al. "The predictive value of the systemic immune-inflammation Index for the progression of lower urinary tract symptoms in men." Asian Pacific Journal of Cancer Prevention: APJCP.  Vol. 24, No. 11, 2023, p. 3845.  Google Scholar          Crossref
10. Naiyila, Xiaokaiti, et al. "A novel insight into the immune-related interaction of inflammatory cytokines in Benign prostatic hyperplasia." Journal of Clinical Medicine. Vol. 12, No. 5, 2023, p. 1821. Google Scholar           Crossref
11. Lin, Tsung-Yen, et al. "Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study." World Journal of Urology. Vol. 42, No. 1, 2024, p. 126. Google Scholar          Crossref
12. Jhang, J‐F., Y‐H. Jiang, and H‐C. Kuo. "Adding Cyclooxygenase‐2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms." International Journal of Clinical Practice. Vol. 67, No. 12, 2013, pp. 1327-33. Google Scholar           Crossref
13. Ozdemir, Ismail, et al. "Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms." Urology. Vol. 74, No. 2, 2009, pp. 431-35. Google Scholar          Crossref